KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Other financing activities (2020 - 2025)

Bionano Genomics' Other financing activities history spans 6 years, with the latest figure at $969000.0 for Q3 2025.

  • For Q3 2025, Other financing activities rose 124.65% year-over-year to $969000.0; the TTM value through Sep 2025 reached $3.5 million, down 41.31%, while the annual FY2024 figure was $3.0 million, 34.68% down from the prior year.
  • Other financing activities for Q3 2025 was $969000.0 at Bionano Genomics, up from $104000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $5.0 million in Q2 2024 and bottomed at -$3.9 million in Q3 2024.
  • The 5-year median for Other financing activities is $566500.0 (2021), against an average of $839142.9.
  • The largest annual shift saw Other financing activities surged 10900.0% in 2021 before it tumbled 97.92% in 2025.
  • A 5-year view of Other financing activities shows it stood at $555000.0 in 2021, then grew by 4.14% to $578000.0 in 2022, then soared by 682.18% to $4.5 million in 2023, then plummeted by 66.62% to $1.5 million in 2024, then crashed by 35.79% to $969000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Other financing activities are $969000.0 (Q3 2025), $104000.0 (Q2 2025), and $919000.0 (Q1 2025).